ArticleImmunity2021
The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.
Open access · greenAbstract read
In one paragraph
Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.
- The soldiers needed to be awakened: Tumor-infiltrating immune cells.Frontiers in genetics · 2022Pooled it
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- HMGB1 Post-Translational Modifications in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: Current Evidence, Emerging Mechanistic Concepts, and Unresolved Questions.International journal of molecular sciences · 2026Review
- The cGAS-STING Pathway: A Double-Edged Regulator of Neuroinflammation and Myelin Regeneration.Molecular neurobiology · 2026Review
- Autoimmune disease patients with comorbid cancer exhibit prominent immunometabolic crosstalk.Science China. Life sciences · 2026Article
- Glycyrrhizin Ameliorates Learning and Memory Impairment via Inhibition of Neuroinflammation in an Alzheimer's Disease Mouse Model SAMP8.International journal of molecular sciences · 2026Article
- Neutrophil extracellular traps promote liver metastasis by impairing NK cell-dependent tumor surveillance via CCDC25.Nature communications · 2026Article
- Peri-weaning, diet-induced activation of an IFNγ-mediated regulatory circuit promotes cDC1 maturation and CD8Nature communications · 2026Article
- The cGAS/STING pathway in cancer: translating innate DNA sensing into therapeutic potential.The Journal of clinical investigation · 2026Review
- Review
- Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer.Bioactive materials · 2026Article
- Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models.Cell reports. Medicine · 2026Article
- Spatial organization of the TNBC tumor microenvironment: multicellular niches, T-cell bottlenecks, and therapeutic opportunities.Journal of translational medicine · 2026Review
- Galectin-9-driven immune evasion constrains radiotherapy-induced systemic antitumor immunity.Journal for immunotherapy of cancer · 2026Article
- The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.Current treatment options in oncology · 2026Review
- Review
- Review
- TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal.Cancer cell international · 2026Review
- Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion.Cell reports. Medicine · 2026Article
- Cellular fragmentation underlies the immunogenicity of irreversible electroporation-mediated tumor cell killing.Bioengineering & translational medicine · 2026Article
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Álvaro de Mingo PulidoDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Kay HänggiDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Daiana P CeliasDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Alycia GardnerDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL 33620, USA.
Jie LiDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL 33620, USA.
Bruna Batista-BittencourtDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL 33620, USA.
Eslam MohamedDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Jimena Trillo-TinocoDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Olabisi OsunmakindeDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL 33620, USA; Department of Health Science and Technology, Aalborg University, Aalborg 29220, Denmark.
Reymi PeñaDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Alexis OnimusDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Molecular Medicine PhD Program, University of South Florida, Tampa, FL 33620, USA.
Tsuneyasu KaishoInstitute for Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
Johanna KaufmannImmuno-Oncology & Combinations Research Unit, GSK, Waltham, MA 02451, USA.
Kristen McEachernTESARO, Waltham, MA 02451, USA.
Hatem SolimanDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Vincent C LucaDepartment of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Paulo C RodriguezDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Xiaoqing YuDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Brian RuffellDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Electronic address: brian.ruffell@moffitt.org.
Moffitt Cancer Center · USUniversity of South Florida · USTesaro (United States) · USWakayama Medical University · JP
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MProject 4P01CA250984 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI KOOMEN, JOHN M · 2021 to 2025
$10.1MPlant-derived extracts regulate immunosuppressive myelopoiesis in Breast cancer patientsR01CA262121 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2021 to 2025
$2.1MRegulation of dendritic cell function and tumor immunity by TIM-3R01CA230610 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RUFFELL, BRIAN · 2019 to 2023
$2.0MFunctional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligandsR01CA233512 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RODRIGUEZ, PAULO CESAR · 2019 to 2023
$2.0MRegulating Intratumoral Leukocytes to Improve Response to ChemotherapyR00CA185325 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RUFFELL, BRIAN · 2015 to 2017
$752kDetermining the role of dendritic cells and spatial localization in anti-tumor immunityF99CA245807 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI GARDNER, ALYCIA · 2019 to 2020
$70kDetermining the role of intratumoral dendritic cells in anti-tumor immunityF31CA224963 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GARDNER, ALYCIA · 2019 to 2019
$30kNCI NIH HHS F31 CA224963NCI NIH HHS F99 CA245807NCI NIH HHS P01 CA250984NCI NIH HHS P30 CA076292NCI NIH HHS R00 CA185325NCI NIH HHS R01 CA230610NCI NIH HHS R01 CA233512NCI NIH HHS R01 CA262121
Abstract
Blockade of the inhibitory receptor TIM-3 shows efficacy in cancer immunotherapy clinical trials. TIM-3 inhibits production of the chemokine CXCL9 by XCR1
Indexed as
AnimalsBiological TransportCell LineCell Line, TumorChemokinesCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseCytoplasmDendritic CellsDNAEndocytosisFemaleHEK293 CellsHepatitis A Virus Cellular Receptor 2HumansImmunotherapyMembrane ProteinscGAS protein, mouseChemokinesCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDNAHavcr2 protein, mouseHepatitis A Virus Cellular Receptor 2Membrane ProteinsNucleotidyltransferasesSting1 protein, mouseSTING ProteinCD103(+) cDC1cGASCXCL10CXCL9dendritic cellsDNASTINGTIM-3type I interferonXCR1(+) cDC1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.